INSIGHTMarkets and EconomicsInsight
The Investment Implications of Deglobalisation
How supply-chain localisation is reshaping manufacturing and capital expenditure
ET&A Research · 28 July 2026 · 12 min read
← All companies
McKesson
MCK · NYSE · Healthcare / Distribution
McKesson Corporation provides healthcare services in the United States and internationally.
Current price
$974.89
▲ +$13.01 (1.35%) today
Share price
Live market data▲ +205.40 (+26.69%)2025-10-13 — 2026-10-14
ET&A View
Last reviewed 22 September 2026
Hold
ET&A sees limited reason to buy aggressively or sell at the current price.
Fair Value
Members
12M Price Target
Members
Preferred Entry
Members
ET&A Score
5.7/ 10Mixed overall
McKesson is a reasonable business with some weak spots.
Is it expensive?
Why we like it
- Little debt — less than a year's earnings would repay it.
- Sales are growing quickly (+12% a year).
- Profits are growing fast (+45%).
What worries us
- Thin profit margins — only about 2% of sales kept as profit.
Business Health
Is the business financially healthy?
Mostly healthy
Revenue, earnings and the balance sheet stand out. Watch margins.
Overall
Good
- Growth Strong
Revenue
$403.4bn · ↑ +12% last year
- Growth Strong
Earnings
$4.6bn · ↑ +45% last year
- Below Average
Margins
Keeps 2% of sales as operating profit
- Average
Cash generation
$5.4bn spare cash a year · 1% of sales
- Strong
Balance sheet
Debt ≈ 0.6 years of earnings
- Yield Weak
Dividend
0.4% yield · Pays out 9% of earnings · covered 11.4×
Investor View
More on McKesson
Open a section for the detail behind the quick view.
Our full viewET&A's complete thesis — why we hold the view we do.Members
The ET&A Score for McKesson Corporation is 5.7/10 — blending a Quant Score of 5.0/10, fundamental conviction of 5.7/10 and valuation attractiveness of 7.9/10. Business quality is assessed as average (EBITDA margin 2%,…
Insight
The complete ET&A view
See our full reasoning, what could drive the shares higher or go wrong, our Fair Value and Preferred Entry, and how our view has changed.
- Our View in full
- What could drive it higher / go wrong
- Fair Value & Preferred Entry
- How our view has changed
Explore Insight →Included with Insight
What could drive it higher — and what could go wrongThe catalysts and risks we are watching.Members
Valuation discussionWhere today's price sits, and how it compares with the company's own history and its peers.Members
Financial and earnings trendsSales, margins, profit, earnings per share and cash, year by year.
Reported annual results, newest first · Market data. “Growth” is the change in sales on the year before.
| Year | Revenue | Growth | Operating margin | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| FY2026 | $403.4bn | +12.4% | 1.6% | $4.8bn | $38.38 | $5.4bn |
| FY2025 | $359.1bn | +16.2% | 1.3% | $3.3bn | $25.72 | $5.2bn |
| FY2024 | $309.0bn | +11.7% | 1.4% | $3.0bn | $22.39 | $3.6bn |
| FY2023 | $276.7bn | — | 1.7% | $3.6bn | $25.03 | $4.6bn |
Next earningsWed, 4 Nov 2026Earnings calendar →
Who it suitsStrategy suitability and investment style.
Long-term growth investors
Also suits: Adventurous investors comfortable with big swings
How it compares with peersOther companies we cover in Healthcare / Distribution.
We don’t cover another company in this sector yet.
Compare McKesson with any company → The model’s own peer calculations are in the Research View.
What the company doesThe full company profile.
McKesson Corporation (MCK) is listed on NYSE, United States, in Healthcare. Market capitalisation is approximately $100.3bn. McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
Healthcare / Distribution · United States
Research ViewOpen the full researchThe full researchFull financial statements, valuation multiples, historical data, forecasts, methodology, scoring calculations and the valuation model.OpenClose
For detailed analysis. Each section opens on its own.
Financial statementsEvery published figure with its source, the market snapshot and connected sheets.
Income
- Revenue
- $403.4bnAnalyst
- Gross profit
- $14.9bnMarket data
- EBITDA
- $7.1bnMarket data
- Operating profit (EBIT)
- $6.5bnMarket data
- Net income
- $4.6bnMarket data
- Earnings per share (EPS)
- $37.31Market data
Growth
- Revenue growth, latest year
- Strong12.4%Analyst
- Revenue growth, 3-year average
- Strong13.4%Calculated
- Earnings growth, latest year
- Excellent44.5%Calculated
- Earnings growth, 3-year average
- Strong10.2%Calculated
- Revenue growth, latest quarter vs a year earlier
- 7.7%Market data
- Earnings growth, latest quarter vs a year earlier
- −17.6%Market data
Margins & returns
- Gross margin
- Below Average3.6%Market data
- EBITDA margin
- 1.7%Market data
- Operating margin
- Below Average1.6%Analyst
- Net margin
- Below Average1.2%Analyst
- Return on equity (ROE)
- Weak−219.2%Analyst
- Return on assets (ROA)
- 4.7%Market data
Cash flow
- Operating cash flow
- $6.9bnMarket data
- Free cash flow
- $5.4bnAnalyst
- Free-cash-flow margin
- Average1.3%Calculated
- Free cash flow ÷ net income
- 1.2×Calculated
Balance sheet
- Cash
- $5.2bnMarket data
- Total debt
- $11.8bnMarket data
- Net debt
- $6.6bnMarket data
- Net debt ÷ EBITDA
- Strong0.6×Analyst
- Current ratio
- 0.9×Market data
Shares & dividends
- Shares outstanding
- 116.6mMarket data
- Market capitalisation
- $100.3bnAnalyst
- Dividend per share
- $3.28Market data
- Dividend yield
- Weak0.4%Analyst
- Payout ratio
- 8.8%Market data
- Analyst — figures entered by ET&A's analyst
- Market data — the live feed (Yahoo Finance)
- Calculated — worked out by ET&A from the figures shown, using the formulas in our methodology
Other published figures
- Price / Sales
- Members
- EV / EBITDA
- Members
- Forward P/E
- Members
- Trailing P/E
- Members
Valuation ratios (P/E, P/S, P/B, EV/EBITDA) are part of ET&A membership — view plans.
Market data
LivePrice$974.89
Day+$13.01 (+1.35%)
52-week range$725.17 – $995.69
vs 52-week low+34.44%
vs 52-week high−2.09%
As of 14 October 2026
- P/E Ratio
- 26.17x
- Sector
- Healthcare / Distribution
- Country
- United States
Valuation multiplesP/E, forward P/E, EV/EBITDA, Price/Sales and FCF yield — today and at Fair Value.Members
Standard ways of comparing the share price with the company’s earnings, sales and cash. Tap the “i” for what each one means.
| Measure | Today | Source |
|---|---|---|
| P/E | Members | |
| Forward P/E | Members | |
| EV/EBITDA | Members | |
| Price/Sales | Members | |
| FCF Yield | Members |
Valuation ratios are part of ET&A membership.
Historical dataValuation history, how our view has changed, and the share-price history.
Share-price history
Use the 5Y and Max ranges on the price chart at the top of the page.
ForecastsWhat analysts expect — market consensus, not ET&A estimates.
Forecasts
- Forward EPS (next year, consensus)
- $50.58Market data
- Expected EPS growth, next year
- Strong14.2%Market data
- Expected revenue growth, next year
- 7.0%Market data
Forecasts are market consensus or calculated from forward EPS — not ET&A estimates, and they can be wrong.
MethodologyHow ET&A values a company and reaches a view.
How we value McKesson
- 1. The right method for the business. Each business is valued on the method that suits its economics — earnings for most companies, book value and returns for banks and insurers, cash flows or dividends where earnings mislead.
- 2. What the business deserves. ET&A builds a fair multiple from the company's own quality, sustainable growth, earnings predictability and risk. History, peers and the market are checked against it, but they don't set it.
- 3. Fair Value. The earnings (or other basis) per share multiplied by that fair multiple, cross-checked against independent methods.
- 4. Preferred Entry. A price below Fair Value that leaves room for the return ET&A requires for the company's risk.
- 5. Is it expensive? Today’s price is placed on ET&A’s Valuation Attractiveness scale — the same measure the ET&A Score uses. Cheap is the Preferred Entry; above Fair Value the shares are Expensive, and Very Expensive once they are more than 25% above it.
Powered by the ET&A Valuation FrameworkHow Fair Value & Preferred Entry work →
Read the full ET&A methodology →How we reach a view
The ET&A View combines our assessment of the business with where today’s price sits against our Preferred Entry and Fair Value. It is a considered judgement, not a mechanical score.
- Business quality
- Financial performance
- Growth outlook
- Debt and financial strength
- Valuation
- Risk
- What could drive it higher
- Buy
- ET&A sees significant upside from the current price with an attractive risk/reward profile.
- Accumulate
- ET&A likes the company but would prefer investors to build exposure gradually.
- Hold
- ET&A sees limited reason to buy aggressively or sell at the current price.
- Reduce
- ET&A believes the current valuation or risk profile makes a smaller position more appropriate.
- Sell
- ET&A believes the downside risk materially outweighs the potential return at the current price.
ET&A Score: ET&A's overall assessment of business quality, valuation, growth and risk, out of 10. It weighs business quality, financial strength, growth, valuation, risk, future prospects.
Powered by the ET&A Company Assessment FrameworkSee the full framework →
Scoring calculationsBehind the ET&A Score and the Business Health ratings.
Behind the ET&A Score
The automatic, rules-based scores that feed our research. The ET&A Score blends these with our own analysis of the business and its value. How the framework works →
ET&A Quant Score
Mixed
Unprofitable · Sound · Strong
Profitability & margins · Unprofitable2.3
Balance sheet · Sound7.1
Price momentum · Strong8.8
Context — not part of the score
- Valuation multiplesFairly priced
- Share-price steadinessHigh volatility
- IncomeLow yield
Valuation and share-price swings describe the shares, not the company, so they are judged in the ET&A Score and View instead.
- Annualised volatility
- Members
- Max drawdown (1y)
- Members
- 12-month return
- Members
- 3-month return
- Members
- P/E
- Members
- Price / Sales
- Members
- EV / EBITDA
- Members
- EBITDA margin
- Members
- Net debt / EBITDA
- Members
- Dividend yield
- Members
The detailed figures behind these scores — price swings, past falls, returns, valuation and margins — are part of ET&A membership. View plans
Based on the factors that could be measured (45% of the model).
Business Health ratings
Each area is scored from 0 to 10 on ET&A’s methodology scales — the same ones our research uses — then given a word: Excellent from 8.5, Strong from 7, Good from 5.5, Average from 4.5, Below Average from 3, Weak below 3. The overall answer is the average of the areas we could rate (at least three); the dividend isn’t part of it.
| Area | Based on | Score | Rating |
|---|---|---|---|
| Revenue |
Rated on 3-year average revenue growth, on ET&A's growth scale. | 7.7 / 10 | Strong |
| Earnings |
Rated on 3-year average earnings growth, on ET&A's growth scale. | 7.0 / 10 | Strong |
| Margins |
The average of operating and net margin, each scored on ET&A's margin scales. A negative margin scores 1 (Weak). | 3.3 / 10 | Below Average |
| Cash generation |
Free cash flow as a share of sales, on ET&A's cash-generation scale. | 4.5 / 10 | Average |
| Balance sheet |
Net debt ÷ EBITDA — roughly how many years of operating earnings would repay the debt — on ET&A's leverage scale. | 7.9 / 10 | Strong |
| Dividend |
Dividend yield on ET&A's income scale. Not part of the overall health rating. | 1.8 / 10 | Weak |
| Overall | Average of the 5 rated areas | 6.1 / 10 | Good |
ET&A's scales
Where each band starts on the scales above. They are fixed and identical for every company we cover; they come straight from ET&A’s methodology, so a company is judged the same way here as in our research.
| Measure | Excellent | Strong | Good | Average | Below Average | Weak |
|---|---|---|---|---|---|---|
| GrowthStructural Growth (Fundamental Conviction) | 18%+ | 10%+ | 5.0%+ | 1.7%+ | −2.5%+ | below −2.5% |
| Operating marginCompetitive Position (Fundamental Conviction) | 29%+ | 20%+ | 13%+ | 7.5%+ | 0%+ | below 0% (loss) |
| Net marginEarnings Durability (Fundamental Conviction) | 23%+ | 15%+ | 9.8%+ | 6.0%+ | 0%+ | below 0% (loss) |
| Free-cash-flow marginCapital Allocation (Fundamental Conviction) | 15%+ | 8.5%+ | 3.8%+ | 1.3%+ | −2.5%+ | below −2.5% |
| Net debt ÷ EBITDAStructural Risk (Fundamental Conviction) | net cash | ≤ 1.5× | ≤ 2.8× | ≤ 3.6× | ≤ 5.0× | above 5.0× |
| Return on equity (banks & insurers)Bank and insurer quality | 16%+ | 12%+ | 9.0%+ | 6.7%+ | 2.7%+ | below 2.7% |
| Equity ÷ assetsBank capital | 7.5%+ | 6.0%+ | 4.7%+ | 4.0%+ | any | — |
| Dividend yieldIncome factor (ET&A Quant Score) | 5.8%+ | 4.0%+ | 2.5%+ | 1.8%+ | 1.0%+ | below 1.0% |
Band floors: Excellent 8.5 · Strong 7 · Good 5.5 · Average 4.5 · Below Average 3 (scores out of 10). Utilities and property companies’ structural debt is scored 6.5, as in ET&A’s risk model.
Valuation model outputsFair Value, the 12-Month Price Target, Preferred Entry and the expected return — and how each was calculated.Members
Peer calculationsThe comparable companies the valuation model used, with their multiples and returns.Members
Detailed assumptionsEvery input the valuation model used, with its source.Members
Research notesNo research notes published yet.
No research notes have been published for McKesson yet.
Need deeper analysis on McKesson? ET&A Professional includes full company notes, valuations and models — or commission bespoke research.
Read more
All insights →
INSIGHTAfrica & Emerging MarketsInsight
Why African Fintechs Must Move Beyond Payments
Payments built Africa’s fintech industry by solving one of the continent’s most visible financial problems. The next generation of winners, however, will need to use that foundation to provide credit, savings, insurance and the broader financial infrastructure that households and businesses still lack.
ET&A Research · 28 July 2026 · 9 min read
INSIGHTTechnology & InfrastructureInsight
Why data centres are becoming an infrastructure asset class
Once viewed as specialist technology facilities, data centres are increasingly becoming essential infrastructure. Rising demand for cloud computing and AI is turning them into a long-term asset class for investors.
ET&A Research · 24 July 2026 · 6 min read